Volume 12, Issue 2 (8-1998)                   Med J Islam Repub Iran 1998 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

HAGHIGHAT M. TREATMENT OF HELICOBACTER PYLORI (H. PYLORI) INFECTION IN CHILDREN: A PROSPECTIVE STUDY COMPA R ING TWO DIFFERENT THERAPEUTIC REGIMENS. Med J Islam Repub Iran 1998; 12 (2) :119-121
URL: http://mjiri.iums.ac.ir/article-1-1016-en.html
From the Division of Pediatric Gastroenterology and Nutrition, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of Iran
Abstract:   (4956 Views)
During a period of 10 months from May to February 1995, 120 children (72 girls, 48 boys) with an age range of 4-16 years (mean age 10.87, S.D.±2.7) with chronic abdominal pain who had an abnormal endoscopy (gastroduodenal mucosal defect) and positive urease test were treated for H. pylori. Patients were treated randomly with either metronidazole and amoxicillin (double therapy, group A) or metronidazole, amoxicillin and bismuth subsalicylate (triple therapy, group B), each for two weeks. 6-8 weeks after completion of treatment, patients were reevaluated by endoscopy and urease test. Endoscopy was normal in 75 cases (63 % ). Of the 45 cases with abnormal endoscopy, 37 patients (82%) were in group A and 8 patients (18%) in group B (p<0.00 l ). The urease test was positive in 44 cases (70%) of group A and 12 cases (20%) of group B (p<0.001). It is concluded that double therapy is relatively ineffective in eradication of H. pylori and triple therapy is less effective in this area compared with reports from industrialized countries. This difference is most probably due to greater drug resistance in this part of the world.
Full-Text [PDF 316 kb]   (1314 Downloads)    
Type of Study: Original Research | Subject: Pediatric

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.